Abstract: A gas flow measuring circuit includes at least one reference resistor and at least one variable resistor that varies in accordance with the characteristics of the flow of a gas and means for determination of the difference between the reference resistor and variable resistor, with at least one current loop arrangement including first current source means coupled in series with said reference resistor and second current source means coupled in series with said variable resistor wherein both resistors are connected to ground for providing an ideally constant current through the respective resistor to produce first voltages across the reference resistor and second voltages across the variable resistor, and voltage measuring means for measuring the voltage difference between said reference resistor and said variable resistor to produce a characteristic voltage difference representative of the characteristics of the gas.

Abstract: A gas flow measuring circuit includes at least one reference resistor and at least one variable resistor that varies in accordance with the characteristics of the flow of a gas and means for determination of the difference between the reference resistor and variable resistor, with at least one current loop arrangement including first current source means coupled in series with said reference resistor and second current source means coupled in series with said variable resistor wherein both resistors are connected to ground for providing an ideally constant current through the respective resistor to produce first voltages across the reference resistor and second voltages across the variable resistor, and voltage measuring means for measuring the voltage difference between said reference resistor and said variable resistor to produce a characteristic voltage difference representative of the characteristics of the gas.

Abstract: The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatitis and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement.

Abstract: The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.

Abstract: The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatit is and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement.

Abstract: The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.

Abstract: The present invention provides a nonhuman animal model for investigating the cause of and the therapy for organ fibrosis. Furthermore, the invention is directed to an animal model comprising a double transgenic, nonhuman animal having the ability to develop a fibrotic phenotype in a conditional and organ-specific manner. Moreover, the invention provides a method for generating the double transgene nonhuman animal.

Abstract: The present invention relates to the use of Phyllanthus for preventing or treating connective tissue proliferations, for maintaining the level of reduced glutathione, for inhibiting lipopolysaccharide (LPS)-induced nitric oxide synthase (NOS) and for inhibiting expression of the cyclooxygenase (COX-2) protein.

Abstract: The invention relates to a drug for treating or preventing intrahepatic cholestasis, which is characterized by containing as active agent at least one compound with the general formula I, where R, R1 and R2 are independent of each other and can each ═H, C1-2-alkyl or C1-3-acyl, R3═H or OR4 and R4═H, C1-2-alkyl or C1-4-acyl, and there is a single or double bond between positions 2 and 3, or a physiologically acceptable salt thereof.

Abstract: In a perifusion apparatus for culturing living cells, the culture medium and the gas in the culture chamber are separated from one another by a gas-permeable wall, the liquid area being entirely filled with the culture medium. Gassing takes place through the gas-permeable wall. Several culture chambers can be interconnected as plug-in modules in such a way that common means can be used for liquid circulation, gassing and optionally thermizing.